高危乳腺癌患者乳房切除术后大分割与常规分割放疗对比:一项随机、非劣效性、开放标签、3期试验
这项在中国单中心开展的随机3期非劣效性试验纳入820例高危乳腺癌患者,比较术后大分割放疗(43.5Gy/15次/3周)与常规分割放疗(50Gy/25次/5周)。中位随访58.5个月时,两组5年局部区域复发率差异未达非劣效性界值以外的程度,大分割组3级急性皮肤毒性更少。
要点
- 大分割放疗组的5年局部区域复发率为8.3%,常规分割组为8.1%,绝对差异0.2%。
- 大分割放疗组3级急性皮肤毒性发生率为3%,低于常规分割组的8%。
- 两组的急性和晚期毒性无显著差异。
核心结论
- 在高危乳腺癌患者中,乳房切除术后大分割放疗的疗效不劣于常规分割放疗,且毒性相似。
- 大分割放疗可提供更便捷的治疗,并使医疗服务提供者能够治疗更多患者。
研究设计与样本
- 随机、非劣效性、开放标签、3期试验,在中国一家学术医院开展。
- 纳入18-75岁、接受乳房切除术且至少有4个阳性腋窝淋巴结或原发肿瘤为T3-4期的患者。
- 患者按1:1随机分配至常规分割放疗组(50Gy/25次/5周)或大分割放疗组(43.5Gy/15次/3周),未进行分层。
- 主要分析采用改良意向性治疗人群(排除随机化后被认为不符合条件或撤回知情同意者)。
- 主要终点为5年局部区域复发,非劣效性界值为5%(相当于风险比<1.883)。
主要发现
- 2008年6月12日至2016年6月16日期间,共820例患者入组并随机分配至常规分割放疗组(n=414)或大分割放疗组(n=406)。
- 改良意向性治疗分析纳入常规分割放疗组409例和大分割放疗组401例。
- 中位随访58.5个月(IQR 39.2-81.8)时,60例(7%)患者发生局部区域复发(大分割放疗组31例,常规分割放疗组29例)。
- 大分割放疗组的5年局部区域复发累积发生率为8.3%(90% CI 5.8-10.7),常规分割放疗组为8.1%(90% CI 5.4-10.6);绝对差异0.2%(90% CI -3.0至2.6),风险比1.10(90% CI 0.72至1.69),非劣效性p<0.0001。
- 大分割放疗组3级急性皮肤毒性发生率低于常规分割放疗组(401例中14例[3%] vs 409例中32例[8%];p<0.0001),其余急性和晚期毒性两组间无显著差异。
关键数值与推荐
- 非劣效性界值为5%,对应风险比<1.883。
- 常规分割放疗方案:50Gy分25次,5周完成。
- 大分割放疗方案:43.5Gy分15次,3周完成。
临床怎么用
- 作者认为,对于高危乳腺癌患者,乳房切除术后大分割放疗不劣于常规分割放疗且毒性相似。
- 作者认为,大分割放疗可提供更便捷的治疗,并使医疗服务提供者能够治疗更多患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To our knowledge, no randomised study has compared postmastectomy hypofractionated radiotherapy with conventional fractionated radiotherapy in patients with breast cancer. This study aimed to determine whether a 3-week schedule of postmastectomy hypofractionated radiotherapy is as efficacious and safe as a 5-week schedule of conventional fractionated radiotherapy. METHODS: This randomised, non-inferiority, open-label, phase 3 study was done in a single academic hospital in China. Patients aged 18-75 years who had undergone mastectomy and had at least four positive axillary lymph nodes or primary tumour stage T3-4 disease were eligible to participate. Patients were randomly assigned (1:1) according to a computer-generated central randomisation schedule, without stratification, to receive chest wall and nodal irradiation at a dose of 50 Gy in 25 fractions over 5 weeks (conventional fractionated radiotherapy) or 43·5 Gy in 15 fractions over 3 weeks (hypofractionated radiotherapy). The modified intention-to-treat population (including all eligible patients who underwent randomisation but excluding those who were considered ineligible or withdrew consent after randomisation) was used in primary and safety analyses. The primary endpoint was 5-year locoregional recurrence, and a 5% margin was used to establish non-inferiority (equivalent to a hazard ratio <1·883). This trial is registered at ClinicalTrials.gov, number NCT00793962. FINDINGS: Between June 12, 2008, and June 16, 2016, 820 patients were enrolled and randomly assigned to the conventional fractionated radiotherapy group (n=414) or hypofractionated radiotherapy group (n=406). 409 participants in the conventional fractionated radiotherapy group and 401 participants in the hypofractionated radiotherapy group were included in the modified intention-to-treat analyses. At a median follow-up of 58·5 months (IQR 39·2-81·8), 60 (7%) patients had developed locoregional recurrence (31 patients in the hypofractionated radiotherapy group and 29 in the conventional fractionated radiotherapy group); the 5-year cumulative incidence of locoregional recurrence was 8·3% (90% CI 5·8-10·7) in the hypofractionated radiotherapy group and 8·1% (90% CI 5·4-10·6) in the conventional fractionated radiotherapy group (absolute difference 0·2%, 90% CI -3·0 to 2·6; hazard ratio 1·10, 90% CI 0·72 to 1·69; p<0·0001 for non-inferiority). There were no significant differences between the groups in acute and late toxicities, except that fewer patients in the hypofractionated radiotherapy group had grade 3 acute skin toxicity than in the conventional fractionated radiotherapy group (14 [3%] of 401 patients vs 32 [8%] of 409 patients; p<0·0001). INTERPRETATION: Postmastectomy hypofractionated radiotherapy was non-inferior to and had similar toxicities to conventional fractionated radiotherapy in patients with high-risk breast cancer. Hypofractionated radiotherapy could provide more convenient treatment and allow providers to treat more patients. FUNDING: National Key Projects of Research and Development of China; the Chinese Academy of Medical Science Innovation Fund for Medical Sciences; and Beijing Marathon of Hope, Cancer Foundation of China.
引用
- Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019. PMID: 30711522. doi:10.1016/S1470-2045(18)30813-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。